Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | PPIB | P23284 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10963283 | 0.88 | MAOB (0.52) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL172911 | 0.87 | MAPT (0.63) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL7304831 | 0.81 | MAPT (0.56) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL10962514 | 0.79 | MMP12 (0.46) | RAB9AKDM4ESMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL428306 | 0.78 | DRD2 (0.50) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL769313 | 0.78 | NPC1 (0.54) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL10964903 | 0.76 | APP (0.50) | MAPTTDP1ARCYP19A1CYP1A2 | |
| SCHEMBL10966821 | 0.76 | FABP6 (0.47) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL10962363 | 0.76 | MAOB (0.50) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL8029261 | 0.75 | NPC1 (0.52) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| EP-1560834-B1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL LAB (ES) | 2008-06-25 | — | — | EP | disclosed |
| EP-1560834-B1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL LAB (ES) | 2008-06-25 | — | — | EP | disclosed |
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-06-01 | — | — | US | disclosed |
| EP-1560834-A1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004043966-A1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL PRODESFARMA S.A. (ES) | 2004-05-27 | — | — | WO | disclosed |
| EP-0025109-B1 | 1-BENZOXEPIN-5(2H)-ONE DERIVATIVES AND THEIR SALTS, AND PROCESSES FOR THEIR PREPARATION | Kali-Chemie Pharma GmbH (DE) | 1985-05-15 | — | — | EP | disclosed |
| US-4320061-A | ANTISPASMODIC AGENTS | KALI-CHEMIE PHARMA GMBH (DE) | 1982-03-16 | — | — | US | disclosed |
| US-4279905-A | GASTROINTESTINAL DISORDERS | KALI-CHEMIE PHARMA GMBH (DE) | 1981-07-21 | — | — | US | disclosed |
| EP-0025109-A2 | 1-Benzoxepin-5(2H)-one derivatives and their salts, and processes for their preparation | Kali-Chemie Pharma GmbH (DE) | 1981-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LTA4H, LTC4S, LTB4R2 | NPC1 2418/4885RAB9A 4576/4885KDM4E 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.